

# New insights into classification and risk stratification of encapsulated thyroid tumors with a predominantly papillary architecture

Chan Kwon Jung<sup>1,2</sup>, So Yeon Park<sup>3</sup>, Jang-Hee Kim<sup>4</sup>, Kennichi Kakudo<sup>5</sup>

<sup>1</sup>Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul;

<sup>2</sup>Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul;

<sup>3</sup>Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam;

<sup>4</sup>Department of Pathology, Ajou University School of Medicine, Suwon, Korea;

<sup>5</sup>Department of Pathology and Thyroid Disease Center, Izumi City General Hospital, Izumi, Japan

Three cases of noninvasive encapsulated papillary *RAS*-like (NEPRAS) thyroid tumor are reported in this issue [1]. The term “NEPRAS” was first used by Ohba et al. in 2019 [2] to designate a noninvasive thyroid tumor showing a complete fibrous capsule, a predominantly papillary architecture, and *RAS* mutation but with subtle nuclear features of papillary thyroid carcinoma (PTC) (Fig. 1). The tumor was considered a borderline thyroid tumor that showed a predominantly papillary structure. The name and concept of “NEPRAS” tumors were proposed as a counterpart of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) having a predominantly follicular architecture. NEPRAS is different from follicular adenoma with papillary hyperplasia because of the appearance of nuclear features of PTC (Fig. 2). The distinction between NEPRAS and NIFTP is based on the presence of papillary structure in NEPRAS tumors (Table 1). NEPRAS tumors with *RAS* mutations or other *RAS*-like mutations are different from encapsulated classic PTCs in that classic PTCs typically harbor the *BRAF* V600E mutation. Therefore, in the diagnostic schema recommended by the World Health Organization (WHO) classification of thyroid tumors, pathologists might have variably classified these noninvasive encapsulated tumors as either benign follicular adenoma or encapsulated PTC depending on the subjective judgment of nuclear features.


The 2017 WHO classification newly adopted a borderline

tumor of the thyroid [3]. Encapsulated follicular-patterned thyroid tumors with borderline behavior include follicular tumor of uncertain malignant potential (FT-UMP), well-differentiated tumor of uncertain malignant potential (WDT-UMP), and NIFTP [3]. FT-UMP has round nuclei that lack PTC-type nuclear features, whereas WDT-UMP and NIFTP share the nuclear features of PTC, including a nuclear score of 2 or 3 on a three-point scoring scale [3]. Although encapsulated follicular-patterned lesions are well defined by the WHO classification, there is a lack of consensus on encapsulated papillary-patterned thyroid tumors that demonstrate subtle nuclear changes. Many diagnostically controversial cases exhibit subtle nuclear features, such as a nuclear score of 2, and therefore pose challenges for accurate diagnosis.

Pathologic diagnosis of a thyroid tumor is fundamentally dependent on pathologists' knowledge and experience in interpreting microscopic findings [4-8]. Due to variable application of loose or strict criteria in assessing the nuclear features of PTC and its invasion of the tumor capsule and vessels, there is discrepancy in diagnosis of encapsulated/well-circumscribed thyroid tumors among pathologists [6-9]. Noninvasive encapsulated papillary-patterned thyroid tumor is diagnosed as encapsulated classic PTC if nuclear features of the tumor are interpreted as nuclear score of 3. However, diagnostic challenges may arise in cases with subtle nuclear changes. In Western practice, equivocal nuclear changes are more easily interpreted as PTC-type nuclear features, whereas most Asian pathologists agree that such nuclear features are insufficient for diagnosis of PTC [10]. As a result, the same tumor can be diagnosed as a follicular adenoma by certain pathologists who apply more stringent criteria for diag-

Received: April 23, 2020 Accepted: April 29, 2020

**Corresponding Author:** Chan Kwon Jung, MD, PhD  
Department of Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Korea  
Tel: +82-2-2258-1622, Fax: +82-2-2258-1627, E-mail: ckjung@catholic.ac.kr



**Fig. 1.** Noninvasive encapsulated papillary *RAS*-like thyroid tumor. (A) The tumor has a thick fibrous capsule and shows cystic change. (B) The solid area is predominantly composed of papillary architecture lined by cuboidal to columnar follicular cells. (C) Psammoma bodies are occasionally seen (arrow). (D) Tumor cells show nuclear enlargement, overlapping, and elongation, with slightly irregular nuclear membranes and dark chromatin, and have no nuclear pseudoinclusions. Molecular analysis revealed *KRAS* G12V mutation.

nosis of PTC.

*RAS*-mutated thyroid tumors demonstrate different histology and biological behavior than tumors with *BRAF* V600E mutation [11]. *RAS* or other *RAS*-like mutations are frequently found in follicular adenoma, NIFTP, and follicular carcinoma with a similarity in the possible spectrum of mutations [12-14]. In PTCs, two molecular subtypes, *BRAF* V600E-like and *RAS*-like types, were proposed by the Cancer Genome Atlas (TCGA) project [11]. Follicular-patterned PTCs typically carry *RAS*-like mutations, including *RAS* mutations, whereas PTCs with papillary architecture have *BRAF* V600E or other *BRAF*-like mutations. However, this rule does not apply in all cases. *RAS*-like mutations can be found in PTCs with papillary architecture. In the TCGA dataset [11], of 250 classic PTCs with molecular classification data, 43 (17.2%) had an *RAS*-like molecular signature, while 16 (6.3%) had *RAS* mutations. Noninvasive en-


capsulated papillary-patterned tumor can also demonstrate PTC-like nuclear features and *RAS* mutations. The tumor was previously classified either as encapsulated classic PTC if it had a nuclear score of 2–3 or as follicular adenoma with papillary hyperplasia if it had a nuclear score of 0 or 1 according to the WHO classification [3]. However, the new diagnostic term “NEPRAS” can reclassify a subset of noninvasive encapsulated papillary-patterned tumors as borderline tumors [2].

NEPRASs share common characteristics of NIFTP as a noninvasive encapsulated tumor, having *RAS*-like mutations, and demonstrating a PTC-type nuclear score of 2. However, NEPRAS lesions are papillary-patterned tumors and can have psammoma bodies (Fig. 1). Because the presence of true papillae and psammoma bodies suggest the probability of classic PTC, these findings are major exclusion criteria for the diagnosis of NIFTP. A nuclear score of 3 and the well-developed nu-



clear features of PTC are not exclusion criteria for NIFTP, but they indicate a higher probability of classic PTC and should serve as an indicator for a more thorough examination of the tu-

mor, including more grossing and immunostaining or molecular testing for *BRAF* V600E (Fig. 3) [15-18]. As encapsulated papillary-patterned tumors with nuclear scores of 3 are fre-



**Fig. 2.** Follicular adenoma with papillary hyperplasia. The tumor is cystic and has a thick complete capsule upon gross (A) and microscopic examination (B). (C) The tumor is composed of a predominantly papillary structure. (D) Tumor cells show basally located, small, and dark nuclei with round contours.


**Table 1.** Classification of encapsulated thyroid tumors with *RAS*-like mutations: a proposal for NEPRAS

Tumor behavior	Invasion	Nuclear score <sup>a</sup>	Papillary architecture	Predominantly follicular growth	
				Presence of true papillae	Absence of true papillae
Benign	Absent	0 to 1	Follicular adenoma with papillary hyperplasia	Follicular adenoma, conventional type	Follicular adenoma, conventional type
Borderline	Absent	2 (rarely 3)	NEPRAS	-	NIFTP
	Questionable	2 (rarely 3)	-	-	WDT-UMP
Malignant	Present	1 (rarely 0)	Follicular carcinoma	Follicular carcinoma	Follicular carcinoma
	Present	2 to 3	Papillary carcinoma, encapsulated classic variant	Papillary carcinoma, encapsulated classic variant with predominant follicular growth	Papillary carcinoma, invasive encapsulated follicular variant

NEPRAS, noninvasive encapsulated papillary *RAS*-like thyroid tumor; NIFTP, noninvasive follicular thyroid neoplasm with papillary-like nuclear features; WDT-UMP, well-differentiated tumor of uncertain malignant potential.

<sup>a</sup>Nuclear score is calculated as the sum of all categories of nuclear features of papillary carcinoma: (1) nuclear size and shape (nuclear enlargement, overlapping, crowding, and elongation), (2) nuclear membrane irregularities (irregular nuclear contours, grooves, and pseudoinclusions), (3) chromatin characteristics (chromatin clearing, margination of chromatin to the membrane, glassy nuclei) [14].





**Fig. 3.** Noninvasive encapsulated classic papillary thyroid carcinoma with predominant follicular growth and *BRAF* V600E. This tumor was initially misdiagnosed as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). (A) The tumor is completely surrounded by a thin fibrotic capsule. (B) The encapsulated tumor is composed of follicular architecture. (C) The tumor cells have florid nuclear features of papillary carcinoma. Nuclear pseudoinclusions and grooves are frequently seen. (D) Immunostaining for *BRAF* V600E (VE1) is positive.

quently positive for the *BRAF* V600E mutation and therefore confidently diagnosed as PTC, a nuclear score of 3 is an exclusion criterion for diagnosis of NEPRAS. While NEPRAS remains a morphologic diagnosis like NIFTP, detection of *RAS*-like low-risk mutations (*RAS*, *BRAF* K601E, *EIF1AX*, *PPARG* fusion, *THADA* fusion, and so forth) further substantiates the diagnosis when molecular results are available. *BRAF*-like mutations (*BRAF* V600E, *ALK*, *RET/PTC*, *NTRK* fusions, etc.) and high-risk mutations (*TERT* promoter, *TP53*, *PIK3CA*, *CTNNB1*, etc.) are essentially exclusionary criteria for diagnosis of NEPRAS and NIFTP lesions. In our case series (Table 2), one NEPRAS tumor had a *KRAS* mutation. In addition, the *NRAS* mutation was found in one NEPRAS tumor showing minimal capsular invasion. Another case had no *RAS* mutations.

Most encapsulated thyroid tumors without invasion are very

indolent and behave like follicular adenoma despite their growth patterns. The management strategy for patients with NEPRAS tumors is similar to those with NIFTP lesions. Thyroid lobectomy is a sufficient treatment for NEPRAS and NIFTP tumors. No further surgery, completion thyroidectomy, or radioactive iodine treatment is required after surgical resection of the primary tumor. Thus, reclassification of a subset of encapsulated classic PTCs into borderline tumors would ultimately lead to more conservative treatment standard and improved quality of life for patients with these tumors.

NEPRAS tumors can progress to invasive cancer just as NIFTP has the potential to progress to an invasive encapsulated follicular variant of PTC (Fig. 4). When NIFTP and NEPRAS tumors develop capsular and/or vascular invasion, they are truly malignant and mostly labelled as PTCs based on the PTC-type nuclear features (Table 1). However, the same cases may be di-




**Table 2.** Cases of noninvasive encapsulated papillary *RAS*-like thyroid tumor and its malignant counterpart with invasion

Reference	Age (yr)	Sex	FNA category <sup>a</sup>	Size (cm)	Invasion	Nuclear score	Papillary component	Cystic change	Psammoma bodies	Molecular profile	Immunohistochemistry
Index case, Ohba et al. (2019) [2]	26	M	II, IV	2.3	Absent	2	Dominant	Present	Present	<i>KRAS</i> G12A; <i>BRAF</i> , <i>NRAS</i> , <i>HRAS</i> , and <i>TERT</i> promoter: wild type	Ki-67 index 1%–2%
Rosario (2020) [1]	35	F	IV	4.0	Absent	2	<1%	NA	NA	<i>BRAF</i> wild type	
	43	F	III	2.2	Absent	2	1%	NA	NA	<i>BRAF</i> wild type	
	48	M	IV	3.5	Absent	2	1%	NA	NA	<i>BRAF</i> wild type	
Case 1	9	M	V	3.7	Absent	2	Dominant	Present	Present	<i>KRAS</i> G12V; <i>BRAF</i> and <i>NRAS</i> : wild type	CK19, focal+; HBME1, focal+; CD56, focal loss; ALK, negative; Pan-Trk, negative
Case 2	38	M	III	1.2	Capsular	2	Dominant	Present	Absent	<i>NRAS</i> Q61R; <i>BRAF</i> , <i>HRAS</i> , <i>KRAS</i> , and <i>TERT</i> promoter: wild type	
Case 3	21	M	II	4.0	Capsular	2	Dominant	Present	Absent	<i>BRAF</i> , <i>NRAS</i> , <i>HRAS</i> , and <i>KRAS</i> : wild type	

FNA, fine-needle aspiration cytology; M, male; F, female; NA, not available.

<sup>a</sup>Based on the categories of the Bethesda System for Reporting Thyroid Cytopathology.



**Fig. 4.** Two cases of the invasive form of noninvasive encapsulated papillary *RAS*-like thyroid tumor. (A, B) A tumor with *NRAS* Q61R. (C, D) The other case without *BRAF* V600E or *RAS* mutations. Both tumors show capsular invasion (A, C). A high-power view of the tumors reveals enlarged round-to-ovoid, overlapping nuclei with few nuclear grooves and less chromatin clearing than seen in classic papillary carcinoma.

agnosed as follicular carcinoma if the nuclear features are interpreted as a nuclear score of 1. Fortunately, these tumors are low-risk cancers despite their name and do not require additional treatment after surgical resection if the tumor is only minimally invasive without angioinvasion. Table 2 summarizes the reported cases in the literature, including our cases.

Although long-term follow-up results of patients with NE-PRAS are not available, it is reasonable to expect an excellent outcome after surgical resection of the tumor. Even when late recurrences do occur, the disease can be successfully treated. While reclassification has important impacts in clinical practice, implementation of new diagnostic criteria and terminologies may provoke resistance in pathologists and clinicians at variable levels. However, these efforts by pathologists will contribute to reducing the incidence rates of overdiagnosis and overtreatment of thyroid cancer.

### Ethics Statement

This study was approved by the Institutional Review Boards of Seoul St. Mary's Hospital (IRB No. KC20ZASI0282), Seoul National University Bundang Hospital (IRB No. B-2004-611-103), and Ajou University Hospital (IRB No. AJIRB-BMR-EXP-20-074) with a waiver of informed consent.

### ORCID

Chan Kwon Jung: <http://orcid.org/0000-0001-6843-3708>

So Yeon Park: <http://orcid.org/0000-0002-0299-7268>

Jang-Hee Kim: <http://orcid.org/0000-0001-5825-1361>

Kennichi Kakudo: <http://orcid.org/0000-0002-0347-7264>

### Author Contributions

Conceptualization: CKJ, KK.

Data curation: CKJ, SYP, JHK, KK.

Formal analysis: CKJ.

Funding acquisition: CKJ.

Investigation: CKJ.

Methodology: CKJ, SYP, JHK, KK.

Project administration: CKJ.

Resources: CKJ.

Supervision: CKJ.

Validation: CKJ, SYP, JHK, KK.

Visualization: CKJ, KK.

Writing—original draft: CKJ.

Writing—review & editing: CKJ, SYP, JHK, KK.

### Conflicts of Interest

C.K.J. and S.Y.P. are the editors-in-chief of *Journal of Pathology and Translational Medicine*. J.H.K. and K.K. are editorial-board members of the journal.

### Funding

This research was funded by a grant (2017R1D1A1B03029597) from the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Science and ICT.

## REFERENCES

- Rosario PW. Noninvasive encapsulated papillary RAS-like thyroid tumor (NEPRAS) or encapsulated papillary thyroid carcinoma (PTC). *J Pathol Transl Med* 2020 Mar 4 [Epub]. <https://doi.org/10.4132/jptm.2020.02.05>.
- Ohba K, Mitsutake N, Matsuse M, et al. Encapsulated papillary thyroid tumor with delicate nuclear changes and a KRAS mutation as a possible novel subtype of borderline tumor. *J Pathol Transl Med* 2019; 53: 136-41.
- Lloyd RV, Osamura RY, Klöppel G, Rosai J. WHO classification of tumours of endocrine organs. 4th ed. Lyon: IARC Press, 2017; 65-91.
- Mete O, Asa SL. Thyroid tumor capsular invasion: the bottom line or much ado about nothing? *Endocr Pathol* 2020 Mar 24 [Epub]. <https://doi.org/10.1007/s12022-020-09621-6>.
- Jung CK, Kim C. Effect of lowering the diagnostic threshold for encapsulated follicular variant of papillary thyroid carcinoma on the prevalence of non-invasive follicular thyroid neoplasm with papillary-like nuclear features: a single-institution experience in Korea. *J Basic Clin Med* 2017; 6: 26-8.
- Hirokawa M, Carney JA, Goellner JR, et al. Observer variation of encapsulated follicular lesions of the thyroid gland. *Am J Surg Pathol* 2002; 26: 1508-14.
- Lloyd RV, Erickson LA, Casey MB, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. *Am J Surg Pathol* 2004; 28: 1336-40.
- Zhu Y, Li Y, Jung CK, et al. Histopathologic assessment of capsular invasion in follicular thyroid neoplasms: an observer variation study. *Endocr Pathol* 2020 Mar 31 [Epub]. <https://doi.org/10.1007/s12022-020-09620-7>.
- Tallini G, Tuttle RM, Ghossein RA. The history of the follicular variant of papillary thyroid carcinoma. *J Clin Endocrinol Metab* 2017; 102: 15-22.
- Kakudo K, Bychkov A, Abelardo A, Keelawat S, Kumarasinghe P.

- Malpractice climate is a key difference in thyroid pathology practice between North America and the rest of the world. *Arch Pathol Lab Med* 2019; 143: 1171.
11. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. *Cell* 2014; 159: 676-90.
  12. Yoo SK, Lee S, Kim SJ, et al. Comprehensive analysis of the transcriptional and mutational landscape of follicular and papillary thyroid cancers. *PLoS Genet* 2016; 12: e1006239.
  13. Jung SH, Kim MS, Jung CK, et al. Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma. *Oncotarget* 2016; 7: 69638-48.
  14. Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. *JAMA Oncol* 2016; 2: 1023-9.
  15. Jeon S, Kim Y, Jeong YM, Bae JS, Jung CK. CCND1 splice variant as a novel diagnostic and predictive biomarker for thyroid cancer. *Cancers (Basel)* 2018; 10: E437.
  16. Cho U, Mete O, Kim MH, Bae JS, Jung CK. Molecular correlates and rate of lymph node metastasis of non-invasive follicular thyroid neoplasm with papillary-like nuclear features and invasive follicular variant papillary thyroid carcinoma: the impact of rigid criteria to distinguish non-invasive follicular thyroid neoplasm with papillary-like nuclear features. *Mod Pathol* 2017; 30: 810-25.
  17. Choden S, Keelawat S, Jung CK, Bychkov A. VE1 immunohistochemistry improves the limit of genotyping for detecting *BRAF(V600E)* mutation in papillary thyroid cancer. *Cancers (Basel)* 2020; 12: E596.
  18. Nikiforov YE, Baloch ZW, Hodak SP, et al. Change in diagnostic criteria for noninvasive follicular thyroid neoplasm with papillary-like nuclear features. *JAMA Oncol* 2018; 4: 1125-6.